BioLineRx Ltd.

BioLineRx Ltd., a biopharmaceutical company develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and cancers

APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer completed Phase 3 clinical trial for the treatment of multiple myeloma.

It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. Incorporated in 2003, BioLineRx is headquartered in Hevel Modi'in, Israel.